What cutaneous manifestations are associated with diabetes and how are they managed?

Cutaneous Manifestations of Diabetes

Diabetes causes numerous skin complications that directly impact morbidity and mortality, with diabetic foot ulcers being the most critical—leading to amputation in 17% of cases and death in 15% within one year if not properly managed 1.

Most Critical Cutaneous Manifestations

Diabetic Foot Ulcers and Infections

The most life-threatening cutaneous complication is the diabetic foot ulcer (DFU), which represents the leading cause of diabetes-related hospitalizations and lower extremity amputations 1. All patients with diabetes require annual comprehensive foot screening starting immediately, with examination frequency increasing based on risk stratification 2.

Risk stratification determines screening frequency:

• IWGDF Risk 0 (no neuropathy/PAD): Annual screening 3
• IWGDF Risk 1 (neuropathy or PAD present): Every 6-12 months 3
• IWGDF Risk 2 (neuropathy + deformity/PAD/callus): Every 3-6 months 3
• IWGDF Risk 3 (prior ulcer/amputation): Every 1-3 months 3

The annual foot examination must include assessment of protective sensation using 10-g monofilament, vibration testing with tuning fork, temperature sensation, pulse palpation (dorsalis pedis and posterior tibial), visual inspection for deformities, and skin integrity evaluation 2. Peripheral neuropathy is the single most common component cause for foot ulceration 2.

Onychomycosis (Fungal Nail Infections)

Diabetics are three times more likely to develop onychomycosis than non-diabetics, affecting approximately 34% of all diabetic patients 4. This is not merely cosmetic—diseased nails with thick sharp edges can injure surrounding tissue and create entry points for bacteria, leading to limb-threatening complications or amputation, particularly in patients with sensory neuropathy who may not notice the injury 4.

For diabetic patients with onychomycosis, terbinafine is the first-line oral antifungal agent 4. The rationale: low risk of drug interactions, no hypoglycemia risk, and itraconazole is contraindicated in congestive heart failure (common in diabetics) due to negative inotropic effects 4. Topical treatments are appropriate for mild-to-moderate infections when drug interaction risk is high 4.

Tinea Pedis (Athlete's Foot)

Commonly coexists with onychomycosis. The most common causative organism is Trichophyton rubrum, followed by T. mentagrophytes 4. Treat fungal infections aggressively to prevent foot ulcers 3, 5.

Other Important Cutaneous Manifestations

Diabetic Dermopathy

Presents as light brown, atrophic, scaly patches typically on the anterior shins. While not directly life-threatening, it serves as a marker of diabetic microvascular disease 6, 7.

Acanthosis Nigricans

Velvety, hyperpigmented plaques in intertriginous areas (neck, axillae, groin). This can appear before diabetes diagnosis and signals insulin resistance 6, 7.

Necrobiosis Lipoidica

Shiny, atrophic, yellow-brown plaques with telangiectasias, typically on anterior shins. Occurs in 0.3-1.6% of diabetics and may ulcerate 6, 7.

Bullosis Diabeticorum

Spontaneous, non-inflammatory blisters on acral surfaces (feet, hands). Rare but pathognomonic for diabetes 6, 7.

Scleroderma Diabeticorum

Thickening and hardening of skin on upper back and posterior neck, occurring in poorly controlled type 2 diabetes 6, 7.

Granuloma Annulare

Annular plaques with raised borders, often on hands and feet. Generalized form associated with diabetes 6, 7.

Xerosis and Pruritus

Dry, itchy skin affects up to one-third of diabetic patients. Managed with emollients and urea-based creams 8.

Management Algorithm

Prevention Protocol (All Diabetic Patients)

Daily foot care education for at-risk patients (IWGDF Risk 1-3) 3:

• Wash feet daily with careful drying between toes
• Apply emollients to dry skin (avoid between toes)
• Cut toenails straight across
• Inspect feet daily for blisters, cuts, scratches, or temperature changes
• Never walk barefoot, in socks without shoes, or in thin-soled slippers—indoors or outdoors 3
• Inspect inside all shoes before wearing
• Avoid tight shoes with rough edges or uneven seams 5

Footwear Recommendations

Risk-stratified approach 3:

• IWGDF Risk 0: Off-the-shelf footwear that fits properly
• IWGDF Risk 1-3: Footwear accommodating foot shape, 1-2 cm longer than foot, width equal to widest part of foot
• IWGDF Risk 2-3 with deformity: Consider extra-depth shoes, custom-made footwear, custom insoles, toe orthoses
• IWGDF Risk 3 with healed plantar ulcer: Prescribe therapeutic footwear with demonstrated plantar pressure relief 3

Treatment of Pre-Ulcerative Signs

Treat aggressively to prevent ulceration 3, 5:

• Remove callus (debridement by trained specialist)
• Protect or drain blisters as needed
• Treat ingrown or thickened nails
• Prescribe antifungal treatment for fungal infections 3, 5
• Repeat treatment until signs resolve and do not recur

Active Ulcer Management

Immediate referral to interprofessional team including podiatrist 2. Classify ulcer type (neuropathic, neuro-ischemic, ischemic), assess for infection, evaluate vascular status, and debride neuropathic ulcers with callus/necrosis immediately 5. For chronic ulcers failing standard care, consider advanced therapies: negative-pressure wound therapy, placental membranes, bioengineered skin substitutes, or topical oxygen therapy 2.

High-Risk Patient Referrals

Refer immediately to foot care specialists 2:

• Smokers with prior lower-extremity complications
• Loss of protective sensation
• Structural foot abnormalities
• Peripheral arterial disease
• History of ulceration or amputation
• Patients on dialysis
• Charcot foot

Critical Pitfalls to Avoid

1. Failing to screen annually: Even asymptomatic patients require systematic foot examination 2
2. Ignoring onychomycosis: This is not cosmetic—it's a gateway to limb-threatening infection 4
3. Delaying treatment of pre-ulcerative signs: Callus, fungal infections, and ingrown nails must be treated before ulceration occurs 3
4. Inadequate patient education: Patients must understand the absolute prohibition on barefoot walking 3
5. Missing PAD: Evaluate pulses and consider ankle-brachial index in all patients with foot complications 2
6. Using itraconazole in diabetics with cardiac disease: Terbinafine is safer 4

The evidence consistently demonstrates that systematic screening, aggressive treatment of pre-ulcerative lesions (especially fungal infections), proper footwear, and patient education directly reduce amputation rates and mortality in diabetic patients.